We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
TCN2 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.15
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
7%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
10%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
37.5
Number of samples
141
Samples
Sample
Description
TPM
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
88.7
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
87.2
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
82.9
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
81.8
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
80.4
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
78.1
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
73.8
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
73.6
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
72.3
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
65.6
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
62.8
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
61.5
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
59.7
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
59.2
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
58.4
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
58.1
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
54.6
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
54.2
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
54.0
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
53.7
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
53.0
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
52.0
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
51.2
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
50.5
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
50.5
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
50.4
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
50.3
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
50.0
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
48.6
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
47.7
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
47.2
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
47.2
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
46.6
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
46.6
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
46.2
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
45.4
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
44.9
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
44.8
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
44.7
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
44.1
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
43.8
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
43.5
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
43.4
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
43.4
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
42.9
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
42.7
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
42.4
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
42.2
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
41.5
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
41.4
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
40.7
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
40.7
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
40.6
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
40.3
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
40.3
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
39.9
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
39.4
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
39.2
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
38.8
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
38.7
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
38.2
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
37.7
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
37.4
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
37.0
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
36.8
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
36.8
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
36.7
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
36.4
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
35.6
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
35.5
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
35.3
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
35.3
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
34.7
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
34.4
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
34.0
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
34.0
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
34.0
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
33.2
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
32.6
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
32.4
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
31.9
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
31.5
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
31.4
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
31.1
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
31.1
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
30.9
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
30.7
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
30.6
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
30.2
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
30.1
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
29.9
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
29.8
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
29.6
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
29.5
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
29.3
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
29.1
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
28.4
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
28.4
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
28.3
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
28.1
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
27.9
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
27.4
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
27.3
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
26.6
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
26.2
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
25.8
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
25.3
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
24.9
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
24.2
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
24.2
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
23.5
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
23.1
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
23.0
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
23.0
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
22.3
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
22.0
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
22.0
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
21.7
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
21.5
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
20.9
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
20.9
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
20.4
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
20.3
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
19.9
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
19.8
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
19.8
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
19.6
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
19.6
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
18.3
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
17.9
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
17.4
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
16.9
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
16.7
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
16.4
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
15.8
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
15.5
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
13.5
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
12.8
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
11.9
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
TCN2 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.013
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
15%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
58%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
9.9
Number of samples
58
Samples
Sample
Description
TPM
AK153
N, NA, stage:NA, dead, 240 days
32.0
AK185
N, NA, stage:NA, alive, 330 days
29.2
AK188
N, NA, stage:NA, alive, 420 days
27.8
AK195
N, NA, stage:NA, dead, 390 days
23.2
AK076
N, NA, stage:NA, alive, 660 days
19.8
AK068
N, NA, stage:NA, alive, 360 days
16.7
AK139
N, NA, stage:NA, dead, 270 days
15.8
AK178
N, NA, stage:NA, dead, 240 days
15.6
AK091
N, NA, stage:NA, dead, 210 days
15.3
AK227
N, NA, stage:NA, alive, 300 days
15.0
AK055
N, NA, stage:NA, dead, 240 days
12.9
AK072
N, NA, stage:NA, dead, 150 days
12.6
AK005
N, NA, stage:NA, dead, 240 days
12.5
AK218
N, NA, stage:NA, dead, 180 days
12.3
AK071
N, NA, stage:NA, dead, 540 days
11.5
AK134
N, NA, stage:NA, dead, 360 days
11.2
AK133
N, NA, stage:NA, dead, 360 days
11.1
AK099
N, NA, stage:NA, dead, 420 days
10.7
AK035
N, NA, stage:NA, dead, 210 days
10.1
AK053
N, NA, stage:NA, dead, 300 days
10.0
AK088
N, NA, stage:NA, dead, 360 days
9.7
AK216
N, NA, stage:NA, dead, 360 days
9.3
AK100
N, NA, stage:NA, alive, 960 days
9.2
AK165
N, NA, stage:NA, alive, 360 days
9.1
AK226
N, NA, stage:NA, dead, 360 days
9.0
AK098
N, NA, stage:NA, dead, 660 days
8.8
AK079
N, NA, stage:NA, dead, 210 days
8.7
AK051
N, NA, stage:NA, dead, 360 days
8.5
AK123
N, NA, stage:NA, dead, 180 days
8.4
AK183
N, NA, stage:NA, alive, 360 days
8.4
AK089
N, NA, stage:NA, dead, 330 days
8.2
AK205
N, NA, stage:NA, dead, 120 days
8.0
AK158
N, NA, stage:NA, dead, 360 days
7.7
AK231
N, NA, stage:NA, dead, 240 days
7.2
AK199
N, NA, stage:NA, alive, 1860 days
7.2
AK041
N, NA, stage:NA, alive, 810 days
7.1
AK173
N, NA, stage:NA, dead, 180 days
6.9
AK030
N, NA, stage:NA, dead, 120 days
6.9
AK167
N, NA, stage:NA, dead, 180 days
6.8
AK003
N, NA, stage:NA, dead, 600 days
6.4
AK149
N, NA, stage:NA, dead, 420 days
6.3
AK236
N, NA, stage:NA, dead, 360 days
6.2
AK102
N, NA, stage:NA, alive, 1740 days
6.0
AK213
N, NA, stage:NA, alive, 2010 days
6.0
AK124
N, NA, stage:NA, alive, 1920 days
5.9
AK074
N, NA, stage:NA, alive, 300 days
5.8
AK103
N, NA, stage:NA, alive, 1320 days
5.7
AK117
N, NA, stage:NA, dead, 210 days
5.4
AK006
N, NA, stage:NA, dead, 360 days
5.4
AK066
N, NA, stage:NA, alive, 960 days
5.3
AK081
N, NA, stage:NA, dead, 180 days
4.8
AK015
N, NA, stage:NA, alive, 720 days
4.7
AK049
N, NA, stage:NA, dead, 180 days
4.5
AK085
N, NA, stage:NA, alive, 660 days
4.5
AK142
N, NA, stage:NA, alive, 90 days
3.8
AK043
N, NA, stage:NA, alive, 660 days
3.6
AK002
N, NA, stage:NA, dead, 570 days
3.5
AK156
N, NA, stage:NA, dead, 330 days
1.3
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0189650004
Tumor
1.4
CPT0087570003
Tumor
1.0
CPT0093550003
Tumor
0.9
CPT0216920008
Tumor
0.7
CPT0104220003
Tumor
0.7
CPT0189750004
Tumor
0.7
CPT0125570003
Tumor
0.7
CPT0204400003
Normal
0.6
CPT0093450003
Tumor
0.6
CPT0186100003
Tumor
0.6
CPT0167530003
Tumor
0.6
CPT0217000004
Tumor
0.5
CPT0064650003
Tumor
0.5
CPT0189850004
Tumor
0.5
CPT0162020003
Tumor
0.5
CPT0204350003
Normal
0.5
CPT0228220003
Tumor
0.4
CPT0087950003
Tumor
0.4
CPT0219080004
Tumor
0.4
CPT0221180003
Tumor
0.4
CPT0089150003
Tumor
0.3
CPT0218690004
Tumor
0.3
CPT0190360004
Tumor
0.3
CPT0162140003
Tumor
0.3
CPT0204330003
Normal
0.3
CPT0217430008
Tumor
0.2
CPT0205890003
Tumor
0.2
CPT0218330004
Tumor
0.2
CPT0204380003
Normal
0.2
CPT0224600003
Tumor
0.2
CPT0189460003
Tumor
0.2
CPT0127420003
Tumor
0.1
CPT0196850003
Tumor
0.1
CPT0190240004
Tumor
0.1
CPT0204410003
Normal
0.1
CPT0217880003
Tumor
0.1
CPT0204420003
Normal
0.1
CPT0087680003
Tumor
0.1
CPT0204360003
Normal
0.1
CPT0207030003
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0168270003
Tumor
0.0
CPT0206880003
Tumor
0.0
CPT0168480003
Tumor
0.0
CPT0206000004
Tumor
0.0
CPT0206560003
Tumor
0.0
CPT0224330003
Tumor
0.0
CPT0206330003
Tumor
0.0
CPT0162100003
Tumor
0.0
CPT0189250003
Tumor
0.0
CPT0201710003
Tumor
-0.1
CPT0168080003
Tumor
-0.1
CPT0199770003
Tumor
-0.1
CPT0182580003
Tumor
-0.1
CPT0218830004
Tumor
-0.1
CPT0225760003
Tumor
-0.1
CPT0217060003
Tumor
-0.2
CPT0104330003
Tumor
-0.2
CPT0207090003
Tumor
-0.2
CPT0205670004
Tumor
-0.2
CPT0168720003
Tumor
-0.2
CPT0224540004
Tumor
-0.3
CPT0168590003
Tumor
-0.3
CPT0167970003
Tumor
-0.3
CPT0002410011
Tumor
-0.4
CPT0167750004
Tumor
-0.4
CPT0093510003
Tumor
-0.4
CPT0218960004
Tumor
-0.4
CPT0189570004
Tumor
-0.4
CPT0206670004
Tumor
-0.5
CPT0161730003
Tumor
-0.6
CPT0168380003
Tumor
-0.6
CPT0078580003
Tumor
-0.6
CPT0205780003
Tumor
-0.6
CPT0218770003
Tumor
-0.6
CPT0167640003
Tumor
-0.6
CPT0167860004
Tumor
-0.6
CPT0217190003
Tumor
-0.8
CPT0204390003
Normal
-1.0
CPT0175060003
Tumor
-1.2
CPT0123530003
Tumor
N/A
CPT0218890004
Tumor
N/A
CPT0224390004
Tumor
N/A
CPT0093590003
Tumor
N/A
CPT0079790003
Tumor
N/A
CPT0204370003
Normal
N/A
CPT0218670003
Tumor
N/A
CPT0204340003
Normal
N/A
CPT0206110003
Tumor
N/A
CPT0208980003
Tumor
N/A
CPT0206780003
Tumor
N/A
CPT0182500003
Tumor
N/A
CPT0217710008
Tumor
N/A
CPT0168830003
Tumor
N/A
CPT0182550003
Tumor
N/A
CPT0125220003
Tumor
N/A
CPT0171580008
Tumor
N/A
CPT0087730003
Tumor
N/A
CPT0205450004
Tumor
N/A
CPT0092440003
Tumor
N/A
CPT0209440003
Tumor
N/A
CPT0127480003
Tumor
N/A
CPT0225730003
Tumor
N/A
CPT0093360003
Tumor
N/A
CPT0206450003
Tumor
N/A
CPT0205570003
Tumor
N/A
CPT0206230003
Tumor
N/A
CPT0064890003
Tumor
N/A
CPT0125510003
Tumor
N/A
CPT0071100003
Tumor
N/A
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.